Article - 21/02/2019 Using neuromedical artificial intelligence responsibly Brain-computer interfaces are the latest developments in the neurotechnology field. They are used to record brain activity, which is then decoded with artificial intelligence techniques and converted into control signals for robots or computers. While this brings hope to severely paralysed people, it also implies risks due to the interest of companies like Google and Facebook in this type of data.https://www.gesundheitsindustrie-bw.de/en/article/news/using-neuromedical-artificial-intelligence-responsibly
Article - 11/02/2019 Natural biopolymers - the sustainable almost-all-rounders Wood pulp as well as hemp and flax are renewable raw materials that can be processed into fibres of a new performance class using innovative technologies. They are environmentally friendly and help to solve waste problems. Products and processes for these fibres of the future are being developed at the DITF Denkendorf. They are suitable for textile and technical applications.https://www.biooekonomie-bw.de/en/articles/news/natural-biopolymers-the-sustainable-almost-all-rounders
Article - 07/02/2019 Artificial intelligence in ophthalmology Retinal diseases such as age-related macular degeneration (AMD) are now treatable. However, it is hard to predict individual disease progression. A group of researchers at the University Eye Centre in Freiburg are currently developing a new system which is hoped will allay fears and improve therapy planning. The system uses artificial intelligence to predict therapeutic outcome from image and patient data. Initial results are already available.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-intelligence-in-ophthalmology
Article - 30/01/2019 candidum – computer-assisted enzyme design Industry has been using enzymes for over a hundred years. While it initially had to content itself with natural enzymes, it is now increasingly possible to design tailor-made biocatalysts with specific properties. The start-up company candidum GmbH from Stuttgart promises to achieve this faster than ever before - mostly thanks to accelerated virtual screening.https://www.gesundheitsindustrie-bw.de/en/article/news/candidum-computer-assisted-enzyme-design
Article - 30/01/2019 candidum – computer-assisted enzyme design Industry has been using enzymes for over a hundred years. While it initially had to content itself with natural enzymes, it is now increasingly possible to design tailor-made biocatalysts with specific properties. The start-up company candidum GmbH from Stuttgart promises to achieve this faster than ever before - mostly thanks to accelerated virtual screening.https://www.biooekonomie-bw.de/en/articles/news/candidum-computer-assisted-enzyme-design
Article - 29/01/2019 Targeted RNA editing with the body’s own enzyme activity Completely new possibilities for research and gene therapy became available following the development of the CRISPR/Cas method for targeted modification of the genome. However, treatment with molecular scissors is not without risk as potential errors are stored in the genome forever. Scientists from Tübingen have developed an alternative method in which the intervention takes place at the RNA level using the body's own enzymes and is thus…https://www.gesundheitsindustrie-bw.de/en/article/news/targeted-rna-editing-with-the-bodys-own-enzyme-activity
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.gesundheitsindustrie-bw.de/en/article/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Article - 24/01/2019 Scientists to combat antibiotic-resistant bacteria in wastewater In Germany, around 1,500 tonnes of antibiotics per year are administered to humans and animals. As a result, more and more bacteria are developing resistance to common antibiotics. As part of HyReKA, a cooperative project funded by the BMBF, scientists led by Professor Thomas Schwartz from the KIT are investigating how antibiotic-resistant pathogens spread and how they can be prevented from doing so.https://www.biooekonomie-bw.de/en/articles/news/scientists-to-combat-antibiotic-resistant-bacteria-in-wastewater
Event - 13/03/2019 - 14/03/2019 Eco Construction – building with wood, recycling and reuse Linz (Austria), Workshop https://www.bio-pro.de/en/events/past-events/eco-construction-building-with-wood-recycling-and-reuse
Event - 24/04/2019 Challenges and Opportunities of Eco-construction in Southeast Europe Zagreb (Croatia), Workshop https://www.bio-pro.de/en/events/past-events/challenges-and-opportunities-of-eco-construction-in-southeast-europe
Event - 09/05/2019 - 10/05/2019 Danube Phytopharma Forum: Converting bio-based resources into successful phytopharmaceutical projects Sofia (Bulgaria), Workshop https://www.bio-pro.de/en/events/past-events/danube-phytopharma-forum-converting-bio-based-resources-into-successful-phytopharmaceutical-projects
Event - 06/03/2019 Biopackaging in the Danube Region Vienna (Austria), Workshop https://www.bio-pro.de/en/events/past-events/pilot-action-biopackaging
Expert interview - 16/01/2019 Cybersecurity is an important issue for the pharmaceutical industry In an increasingly interconnected world, the pharmaceutical and biotechnology sectors need to be aware of cybersecurity threats in manufacturing. We talked about these threats with Holger Mettler who is in charge of computer system validation and cybersecurity at Exyte (formerly M + W), a global enterprise that designs, engineers and constructs complex manufacturing facilities and buildings for the life sciences industry.https://www.gesundheitsindustrie-bw.de/en/article/news/cybersecurity-is-an-important-issue-for-the-pharmaceutical-industry
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.gesundheitsindustrie-bw.de/en/article/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Article - 10/01/2019 Stocktaking and recommendations for action: the BBAW’s fourth gene technology report In the new gene technology report, the interdisciplinary working group of the Berlin-Brandenburg Academy of Sciences (BBAW) takes stock of gene technology developments in Germany during the past few decades, and discusses the societal, legal and ethical challenges associated with these technologies in the future. The report is highly topical due to the controversy surrounding the ruling of the European Court of Justice on CRISPR/Cas9 genome…https://www.biooekonomie-bw.de/en/articles/news/stocktaking-and-recommendations-for-action-the-bbaws-fourth-gene-technology-report
Company profile - 09/01/2019 HQS Quantum Simulations for industrial quantum mechanics applications The door to the quantum world is opening wider and wider. Behind it is a whole new view of materials and molecules. Quantum mechanics applications not only benefit science, they also offer huge economic potential. The Karlsruhe start-up HQS Quantum Simulations is playing a pioneering role in quantum simulations for the chemical and pharmaceutical industries.https://www.gesundheitsindustrie-bw.de/en/article/news/hqs-quantum-simulations-for-industrial-quantum-mechanics-applications
Dossier - 28/08/2018 With molecular diagnostics to biomarker-based personalised therapy Diagnosing suitable biomarkers is a prerequisite for tailoring personalised therapies to patient heterogeneity. Genetic tests and genome sequencing play a key role in these diagnoses. Up until now, personalised therapy has achieved the greatest success in the field of oncology. However, personalised treatments are also gaining in importance for treating other diseases.https://www.gesundheitsindustrie-bw.de/en/article/dossier/with-molecular-diagnostics-to-biomarker-based-personalised-therapy
Overview Perspectives on the bioeconomy https://www.biooekonomie-bw.de/en/bw/definition/perspectives-on-the-bioeconomy
Overview Processes and technologies in the bioeconomy https://www.biooekonomie-bw.de/en/bw/definition/processes-and-technologies-in-the-bioeconomy
Event - 18/10/2018 Tourism meets Bioeconomy Sofia (Bulgaria), Workshop https://www.bio-pro.de/en/events/past-events/tourism-meets-bioeconomy
Funding Future Insight Prize Funding programme, Funded by: Merck KGaA, sb_search.searchresult.label.programSubmissionDate: 31/12/2022 https://www.gesundheitsindustrie-bw.de/en/database/funding/future-insight-prize
Funding Future Insight Prize Funding programme, Funded by: Merck KGaA, sb_search.searchresult.label.programSubmissionDate: 31/12/2022 https://www.bio-pro.de/en/service/funding/future-insight-prize